Radio‐Activated Selenium‐Doped Janus Ag/Ag <sub>2</sub> Se <sub>x</sub> S <sub>y</sub> Nanoparticles for Precise Cancer NIR‐II Fluorescence Imaging and Radiosensitization Therapy
The efficacy of radiotherapy (RT) is often limited by insufficient tumor selectivity and suboptimal therapeutic responses. To overcome these problems, a new kind of selenium-doped Ag/Ag<sub>2</sub>S Janus nanoparticles (Ag/Ag<sub>2</sub>Se<sub>x</sub>S<sub>y</sub> JNPs) is presented as radio-responsive molecular probes for precise tumor imaging and enhanced radiosensitization. By adjusting the selenium precursor input, heterojunction nanoparticles with tunable doping ratios are synthesized, optimizing X-ray absorption and energy storage properties. Upon X-ray irradiation, the Ag/Ag<sub>2</sub>Se<sub>x</sub>S<sub>y</sub> JNPs interact with overexpressed hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in tumor cells, generating highly toxic hydroxyl radicals (·OH), which effectively induce tumor cell apoptosis. Additionally, Selenium incorporation improves electron-hole pair separation efficiency and enhances the photocurrent response, promoting increased electron transfer and ·OH generation, thus amplifying reactive oxygen species (ROS) production and enhancing radiosensitization. Furthermore, the fluorescence "OFF-ON" mechanism, triggered by H<sub>2</sub>O<sub>2</sub>-induced etching of silver allows real-time monitoring of H<sub>2</sub>O<sub>2</sub> levels via the second near-infrared window (NIR-II) fluorescence (FL) imaging "Turn On", which delineates tumor boundaries for precise RT and reduce side effects to normal tissue. This dual-functional platform not only enables real-time tracking but also enhances therapeutic outcomes, offering a promising approach to precision cancer treatment.
Authors
- Zhanyuan Li
- Jibin Song (ORCID: https://orcid.org/0000-0003-4771-5006)
- Jing Mu (ORCID: https://orcid.org/0000-0002-7508-1461)
- Qunsheng Li (ORCID: https://orcid.org/0000-0002-1908-9418)
- Hanxun Zou (ORCID: https://orcid.org/0000-0002-2913-3806)
- Huiqin Zhou
- Ling Chen (ORCID: https://orcid.org/0000-0002-9748-4376)
- Shiyu Wang (ORCID: https://orcid.org/0000-0002-4050-6319)
- Wei Huang (ORCID: https://orcid.org/0000-0002-7606-345X)
- Jingjing Cao (ORCID: https://orcid.org/0000-0001-7335-3876)
- Jimei Wang
- Kang Zhu (ORCID: https://orcid.org/0000-0002-8443-2315)
- Yixi Cao (ORCID: https://orcid.org/0009-0000-3331-1882)
Institutions
- University of Jinan (CN)
- Shandong Tumor Hospital (CN)
- Peking University Shenzhen Hospital (CN)
- Shandong First Medical University (CN)
- Putian University (CN)
- Beijing University of Chemical Technology (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1002/advs.202417828
- Citations
- 7
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 4.72
Funders
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities